

0/5/6

DIALOG(R) File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.

009565130

WPI Acc No: 1993-258678/199332

XRAM Acc No: C93-114921

New von Willebrand factor antagonist fusion proteins - comprising antagonist fragment linked to stabilising protein, useful as antithrombotic agents

Patent Assignee: RHONE POULENC RORER SA (RHON)

Inventor: FLEER R; FOURNIER A; GUITTON J; JUNG G; YEH P

Number of Countries: 022 Number of Patents: 006

Patent Family:

| Patent No | Kind | Date | Applicat No | Kind | Date | Week | |
|------------|------|----------|-------------|------|----------|--------|---|
| WO 9315200 | A1 | 19930805 | WO 93FR87 | A | 19930128 | 199332 | B |
| FR 2686901 | A1 | 19930806 | FR 921066 | A | 19920131 | 199344 | |
| FI 9403565 | A | 19940729 | WO 93FR87 | A | 19930128 | 199437 | |
| | | | FI 943565 | A | 19940729 | | |
| NO 9402840 | A | 19940929 | WO 93FR87 | A | 19930128 | 199444 | |
| | | | NO 942840 | A | 19940729 | | |
| EP 625199 | A1 | 19941123 | EP 93904131 | A | 19930128 | 199445 | |
| | | | WO 93FR87 | A | 19930128 | | |
| JP 7503369 | W | 19950413 | JP 93512988 | A | 19930128 | 199523 | |
| | | | WO 93FR87 | A | 19930128 | | |

Priority Applications (No Type Date): FR 921066 A 19920131

Cited Patents: 2.Jnl.Ref; EP 255206; EP 41362; WO 9113093; WO 9206999; WO 9217192; WO 9300357

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9315200 A1 F 48 C12N-015/12

Designated States (National): CA FI JP NO US

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

FR 2686901 A1 36 C12P-021/02

EP 625199 A1 F C12N-015/12 Based on patent WO 9315200

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

JP 7503369 W C12N-015/09 Based on patent WO 9315200

FI 9403565 A C12N-000/00

NO 9402840 A C12N-015/62

Abstract (Basic): WO 9315200 A

New recombinant polypeptides comprise: (a) an adhesive portion derived from the structure of von Willebrand's factor (vWF) and capable of at least partially antagonising the binding of vWF to platelets and/or subendothelium, and (b) a portion permitting the stabilisation and presentation of (a) in vivo.

Also claimed are: (1) a nucleotide sequence coding for (I); (2) an expression cassette comprising sequence (1) under the control of a transcription initiation region and opt. a transcription termination region; (3) a self-replicating plasmid contg. cassette (2); and (4) a recombinant eukaryotic or prokaryotic cell contg. sequence (1), cassette (2) or plasmid (3).

USE/ADVANTAGE - (I) are platelet aggregation inhibitors, some with higher activity than RG12986 (Bio Tech., 10, 66, 1992) and some being

) effective in the absence of botrocetin-type cofactors. They are esp.
useful for treatment or prophylaxis of thrombosis.

Dwg. 0/9

Title Terms: NEW; FACTOR; ANTAGONIST; FUSE; PROTEIN; COMPRISE; ANTAGONIST;
FRAGMENT; LINK; STABILISED; PROTEIN; USEFUL; ANTITHROMBOTIC; AGENT

Derwent Class: B04; D16

International Patent Class (Main): C12N-015/09; C12N-015/12; C12N-015/62;
C12P-021/02

International Patent Class (Additional): A61K-037/02; A61K-038/43;
C07K-013/00; C07K-019/00; C12N-001/19; C12N-005/10; C12N-015/14;
C12N-015/81

File Segment: CPI